Abstract: A method for delivering a therapeutically effective drug via a hardenable ceramic hydraulic cement composition including a first component of at least one sodium or calcium salts of inorganic and organic acids, a second component of at least one alkaline, and optionally third and fourth components including an organic carboxylic acid and pure water, respectively, wherein the cement composition is implanted in an animal or human body, hardens, and then degrades in situ after time to releases a amount of the drug into a locally targeted area.
Abstract: The invention provides cosmetic creams containing granular components for cleansing and scrubbing the skin, which contain granules of a salt, in particular sodium or potassium chloride, and which are stable under storage and use conditions. In an embodiment of the invention, no rinsing is required after use. The invention also provides a process for making the cosmetic creams by mixing a solution of a salt, in the amount contained by a solution that is saturated at a temperature not lower than room temperature, with the water soluble ingredients of the cream base, emulsifying the mixture with the components of the oily phase of the cream base to obtain a complete mixture, homogenizing and cooling the complete mixture, adding fragrances and preservatives and optionally additives, and finally adding solid salt particles while continuing to homogenize said mixture.
Abstract: A composition for relief of symptoms of colds and influenza, containing, by weight, about 80-88% olive leaf extract powder containing oleuropein, about 5-10% neem leaf powder and up to about 8% of a homeopathic blend for symptom relief which preferably comprises aconitum napelius, belladonna, eupatorium perfoliatum, gelsemium sempervirens, Echinacea angustifolia and ferrum phosphoricum.
Abstract: This invention provides reagents and methods for specifically delivering antibiotic, antimicrobial and antiviral compounds, drugs and agents to phagocytic mammalian cells. The invention also relates to specific delivery to and uptake of such compounds by phagocytic cells. The invention specifically relates to reagents and methods for facilitating the entry of antibiotic, antimicrobial and antiviral compounds, drugs and agents into phagocytic cells. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising such antibiotic, antimicrobial or antiviral compounds, drugs and agents conjugated to, impregnated with or coated onto particulate carriers generally termed microparticles. In particular embodiments, the antibiotic, antimicrobial and antiviral compounds, drugs and agents are covalently linked to a microparticle via a specifically-degradable linker molecule which is the target of a microorganism-specific protein having enzymatic activity.
Type:
Grant
Filed:
July 10, 2000
Date of Patent:
September 24, 2002
Assignee:
Enzrel, Inc.
Inventors:
Michael J. Meredith, Milton B. Yatvin, Richard L. Pederson
Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.
Abstract: Controlled release dosage forms useful in the treatment and/or prophylaxis of dementia, including Alzheimer's disease, in mammals, and for enhancing amyloid precursor protein processing along a non-amyloidogenic pathway in patients suffering from, or at risk of developing, Alzeimer's disease.
Abstract: Disclosed herein is a porcine intra-vaginal device of a shape and size adapted to be positionable in the vaginal tract across the hymenal ring of a target animal (e.g., a gilt) to extend to both sides of the hymenal ring of the animal. The device once inserted delivers progesterone from a progesterone impreganated matrix on either side of the hymenal ring, the progesterone releasing surface being at least 150 cm2 in total area. Variable geometry means (preferably for vestibular engagement) ensure retention of the devices (e.g., for at least 7 to 14 days) where, in the preferred device, the progesterone load of from 1.9 to 2.5 g within 1.2 mm of the release surface can, by maintaining a progesterone blood plasma level (equating to a progestrone blood plasma level in excess of 4 ng/mL measured in an ovariectomised animal), ensure or prompt the onset of oestrus within 3 to 5 days after device removal.
Type:
Grant
Filed:
March 2, 2000
Date of Patent:
September 3, 2002
Assignee:
Interag
Inventors:
Michael John Rathbone, Shane Burccraff, James Frederick Pharaoh
Abstract: A composition for treating keratinous materials, particularly human hair, is disclosed, The composition is packaged in an aerosol device and forms a lacquer at the outlet of the device. Said composition contains (a) at least one silicone graft polymer including a polysiloxane portion and a portion consisting of a non-silicone organic chain, where one of said portions forms the main polymeric chain while the other is grafted onto said main chain; (b) at least 30 wt % of water, (c) at least one propellant; and (d) an organic solvent in an amount of 0-25 wt %; the above percentages by weight being based on the total weight of the composition in the aerosol. Such aqueous lacquers are useful for fixing and/or styling and/or conditioning hair.
Abstract: The form B of paroxetine maleate polymorph is characterized by determined data of X ray diffraction: it has a chemical stability which is superior to that of the form A of paroxetine maleate. This superior stability enables to use the new polymorph for the fabrication of medicaments intended to the treatment of troubles related to dysfunctions of the central nervous system. The process for producing the paroxetine maleate comprises the preparation of paroxetine maleate solution and a consequent precipitation.
Type:
Grant
Filed:
January 4, 2001
Date of Patent:
August 27, 2002
Assignee:
Medichem, S.A.
Inventors:
Alberto Stampa Diez del Corral, Jordi Bosch Lladó, Elias Molins Grau, Maria del Carmen Onrubia Miguel
Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
Type:
Grant
Filed:
January 20, 2000
Date of Patent:
August 13, 2002
Assignee:
West Pharmaceutical Services Drug Delivery & Clinical
Research Centre Limited
Abstract: A method of treating disorders involving the urethrogentical tract by administering to pateints in need therof therapeutically effective amounts of the desethyl metabolite of oxybutynin and/or the optically active isomers thereof, which are free from said cardiac side effect of oxybutynin, while maintaining the therapeutic activities of oxybutynin or the optically active isomers thereof.
Abstract: An exfoliating scrub contains in a mild cream or gel base a therapeutically effective concentration of niacinamide and an abrasive exfoliating agent, preferably powdered walnut shells. The scrub is applied topically to areas of the skin that are to be treated and is massaged into the skin. The scrub is thereafter removed. The scrub contains niacinamide in an amount between about 1 and 20% by weight.
Abstract: The invention is directed toward a sterile bone structure for application to a bone defect site to promote new bone growth at the site comprising a partially demineralized cortical bone structure, said bone structure comprising a cross sectional surface are ranging from 85% to 95% of the original bone surface area before demineralization with the remaining partially demineralized cortical bone structure having an outer demineralized layer ranging in thickness from about 0.05 mm to about 0.14 mm and a mineralized core.
Abstract: A theophylline sustained release tablet obtained by coating core granules composed mainly of theophylline with a layer of a coating film composed of a hydrophobic material and a plastic excipient and optionally containing an enteric polymer material to form coated granules and then by compressing the coated granules together with a disintegrating excipient.
Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.
Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.
Abstract: The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Methods of delivery a pharmaceutically active agent to the posterior segment of the human eye are also disclosed.
Abstract: Devices, methods, and compositions for treating vaginal fungal, bacterial, viral and parasitic infections by intravaginal or transvaginal administration of therapeutic and/or palliative antifungal, antibacterial, antiviral or parasiticidal drugs to the vagina or to the uterus.
Type:
Grant
Filed:
July 11, 2000
Date of Patent:
July 9, 2002
Assignee:
UMD, Inc.
Inventors:
Merida A. D'Augustine, James H. Liu, Donald C. Harrison
Abstract: A biodegradable carrier for delivery of a selected bioactive molecule into a targeted host cell containing an amphiphilic polyester-polycation copolymer and an amphiphilic polyester-sugar copolymer. The carrier is particularly useful for delivery of a negatively charged bioactive molecule such as a nucleic acid. The invention improves delivery efficiency by providing a particulate gene carrier for which the particle size and charge density are easily controlled by various means. Various kinds of ligands and other functional compounds may be also be introduced to the carrier. The carrier may be used for delivering a targeted host cell with a bioactive molecule.